Close menu




September 2nd, 2025 | 07:50 CEST

INSIDER ALERT at Evotec! Valneva with new TARGET PRICE! Vidac Pharma stock soon to reach new ALL-TIME HIGH?

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: Bayer AG

Finally! Insiders are sending an important signal at Evotec. The stock has not yet reacted, but in the medium term, this could turn out to be a buy signal. Skepticism still prevails at present. Analysts are bullish on Vidac Pharma. In the fall of 2024, the biotech stock had multiplied in value. Is it now heading back toward its all-time high? According to analysts, significantly higher price gains are possible. Valneva, on the other hand, is not for the faint of heart. After doubling in price within a few weeks, the stock has plummeted again. Analysts recommend buying, but are significantly lowering their price target.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Vidac Pharma: Analysts remain bullish

    Will the multiplication repeat itself? In the fall of 2024, Vidac Pharma's stock surged from below EUR 0.30 to EUR 1 following the release of positive study data. The biotech company's stock is currently trading at EUR 0.49. According to analysts at Sphene Capital, significantly more than EUR 1 is possible. Their price target for the "promising biotech story in the oncology sector" is EUR 4.30.

    The positive assessment is based on a new scientific study. This study underpins the Company's innovative therapeutic approach. The study confirms that restoring mitochondrial function makes tumor cells more sensitive to chemotherapy. This is precisely where Vidac Pharma's mechanism of action comes into play: by blocking the binding of hexokinase 2 to the VDAC channel in the mitochondria, the so-called "Warburg effect," which drives the excessive sugar metabolism of cancer cells, is disrupted.

    Vidac is currently advancing two clinical programs. The first, VDA-1102 for actinic keratosis—a precursor to non-melanoma skin cancer—received the STEP Seal from the European Commission in June of this year, recognizing it as a biotech project particularly worthy of support. It is also intended to treat cutaneous T-cell lymphoma (CTCL) and, following positive interim results, has progressed directly into Phase 2. Here, half of the patients showed an objective response, and one-fifth even achieved complete remission.

    The other promising drug is VDA-1275. It is still in the preclinical stage. If Vidac Pharma advances this candidate to the clinical phase, analysts see significant additional upside potential. Being particularly conservative, the current valuation does not account for terminal value or potential upfront or milestone payments from licensing deals.

    Evotec: Insider strikes

    Is this the signal to buy Evotec? On August 20, we criticized the fact that, despite the decline in Evotec's share price since February, there had been no insider purchases. Dr. Christian Wojczewski has apparently taken this to heart. He has been the CEO of the struggling German biotech company for over a year now.

    Last week, the news finally came: Wojczewski purchased around 50,000 Evotec shares. He invested a total of EUR 295,905. The fact that the share price has hardly reacted so far indicates the extent to which confidence in the biotech company is shaken and how critically the new "profit before growth" strategy is viewed. Nevertheless, this could well have been a buy signal in the medium term.

    Valneva: Buy shares after the crash?

    First Berlin has slashed its target price for Valneva shares. Although the "Buy" recommendation has been confirmed, analysts now see the fair value of the biotech stock at only EUR 6.30, down from EUR 8.10 previously. The price target was accompanied by a reduction in the sales forecast for the drug IXCHIQ. Previously, the US FDA had suspended approval for Valneva's chikungunya vaccine IXCHIQ for all age groups (presumably permanently). Four serious adverse events (SAEs) were cited as the reason for this.

    Initially, there were reports in May of SAEs, particularly in older people with multiple underlying conditions. At that time, the EMA and the FDA suspended the use of IXCHIQ in this age group. After the authorities lifted these restrictions, Valneva's share price more than doubled within a few weeks. IXCHIQ has not yet been suspended by the EMA. Nevertheless, analysts expect fewer orders despite the current chikungunya outbreak in parts of Africa, Southeast Asia, France, and Italy, and anticipate that Bavarian Nordic's competing chikungunya vaccine, VIMKUNYA, will be favoured.

    Analysts are now focusing on Valneva's vaccine candidate VLA15 against Lyme disease. The results of the Phase 3 study on VLA15 are expected to be available either at the end of this year or in early 2026. Subject to positive Phase 3 data and regulatory approval, Valneva is expected to receive milestone payments totaling USD 143 million from its partner, Pfizer, in 2027. Currently, there is no vaccine available to prevent Lyme disease in humans.


    It is uncertain whether the development seen in the fall of 2024 will repeat itself for Vidac shares. However, analysts are convinced of the biotech company's long-term prospects. Evotec also has potential in the medium term, but trust still needs to be rebuilt. Valneva lives up to its reputation as a speculative stock.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on October 16th, 2025 | 07:20 CEST

    Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • blockbuster
    • Technology

    In the biotech sector, a single technology can often determine success or failure. Canadian-German company BioNxt Solutions is taking a different approach, relying on three pillars, each targeting major markets and advancing established blockbusters from leading pharmaceutical companies. October has already brought decisive progress, from accelerated patent protection to concrete milestones in development. These concentrated positive signals show that BioNxt Solutions not only has a promising concept, but also the strategy and operational strength to turn it into value. A closer analysis is worthwhile.

    Read

    Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST

    Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health

    • Biotechnology
    • AI
    • healthtech
    • Sustainability
    • plantbased

    The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.

    Read

    Commented by Nico Popp on October 16th, 2025 | 07:00 CEST

    Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech

    • Biotechnology
    • AI
    • Biotech
    • Cancer

    Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.

    Read